Tafenoquine in Patients With Mild to Moderate COVID-19
Trial details
- Registry ID
- NCT04533347
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ARAKODA™; KODATEF™
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Tafenoquine in Patients With Mild to Moderate COVID-19NCT04533347 | 60 Degrees Pharmaceuticals LLC | Phase 2 | Completed | 2022-06-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |